Cerebral ischaemia - Using nonsteroidal anti-inflammatory drugs Factor
NB For balance of probability cases, this factor is limited to a particular type of a non-steroidal anti-inflammatory drug (NSAID) – Cyclo-oxygenase 2 inhibitor drugs.
There are many anti-inflammatory drugs that do not contain steroids. Most commonly they are treatment for arthritic conditions but may also be used for muscle strains associated with sporting injuries. Although aspirin is a NSAID, it is excluded from this SOP factor. Examples of NSAIDs (other than aspirin) include:
- Phenylbutazone (Butazolidine - BTZ)
- Indomethacin (Indocid, Hicin, Indomed)
- Naproxen (Naprosyn, Naprogesic)
- Ibuprofen (Brufen, Nurofen, Rafen)
- Piroxicam (Feldene, Fensaid, Mobilis)
- Ketoprofen (Orudis, Oruvail)
- Sulindac (Clusinol, Clinoril)
- Tenoxicam (Tilcotil)
- Diclofenac sodium (Voltaren, Fenac)
- Celecoxib (Celebrex)
- Rofecoxib (Vioxx)
These are usually prescribed medications, but some, such as Nurofen and Naprogesic, are available without a doctor's prescription.
Last reviewed for CCPS 24 May 2007.
Investigative Documents
| Type | Title | PDF Format | Word Format |
|---|---|---|---|
| Claimant Report | Nonsteroidal Anti-Inflammatory Drugs (excluding Aspirin) | ||
| Medical Report | Treatment with NSAIDs (excluding Aspirin) |
Preliminary questions [37188]
36394 there is some evidence that a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, may be a factor in the development of the condition under consideration.
36395 the veteran used a drug as specified in the reasonable hypothesis Statement of Principles before the clinical onset of the condition under consideration.
36396 the veteran's use of a drug as specified in the reasonable hypothesis Statement of Principles was materially contributed to by treatment of an injury or illness which is identifiable.
37189 the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and VEA service for the clinical onset of cerebrovascular accident.
37190 the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and operational service for the clinical onset of cerebrovascular accident.
or
37191 the veteran has established the causal connection between treatment with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs and eligible service for the clinical onset of cerebrovascular accident.
Clinical onset and operational service [37190]
36399 the identified illness or injury, for which the veteran used a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, is causally related to operational service.
Clinical onset and eligible service [37191]
36752 for treatment of the identified illness or injury, the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs for a period specified in the balance of probabilities Statement of Principles before the clinical onset of the condition under consideration.
36405 the identified illness or injury, for which the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs, is causally related to eligible service.